Search Results - "Knop, A.S."

391P Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered by Bjerrum, A., Henriksen, A.F., Knop, A.S., Berg, T., Tuxen, I.E.V., Lassen, U.N., Petersen, T.S.

Get full text

Locoregional lymph node metastasis from occult breast cancer: Treatment options and prognosis in Denmark by Nærum, A.W., Holm-Rasmussen, E.V., Vejborg, I., Knop, A.S., Lænkholm, A.V., Kroman, N., Tvedskov, T.F.

Get full text

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] by de Azambuja, E., Piccart-Gebhart, M., Fielding, S., Townend, J., Hillman, D.W., Colleoni, M., Roylance, R., Kelly, C.M., Lombard, J., El-Abed, S., Choudhury, A., Korde, L., Vicente, M., Chumsri, S., Rodeheffer, R., Ellard, S.L., Wolff, A.C., Holtschmidt, J., Lang, I., Untch, M., Boyle, F., Xu, B., Werutsky, G., Tujakowski, J., Huang, C.-S., Baruch, N.B., Bliss, J., Ferro, A., Gralow, J., Kim, S.-B., Kroep, J.R., Krop, I., Kuemmel, S., McConnell, R., Moscetti, L., Knop, A.S., van Duijnhoven, F., Gomez, H., Cameron, D., Di Cosimo, S., Gelber, R.D., Moreno-Aspitia, A.

“…Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer…”
Get full text